The American Association for Cancer Research (AACR) is launching a new journal, Blood Cancer Discovery. The journal will be the ninth in the AACR’s prestigious portfolio of scientific publications, including the highly cited journal, Cancer Discovery.
Blood Cancer Discovery will feature high-impact, peer-reviewed articles describing major advances in basic, translational, and clinical research on all subtypes of leukemia, lymphoma, myeloma, and associated diseases. The journal will provide a new platform for the dissemination of pace-setting advances generated by the worldwide community of blood cancer researchers and physician-scientists.
Taking the helm as founding Editors-in-Chief will be Dr. Riccardo Dalla-Favera, and Dr. Kenneth C. Anderson, both distinguished international leaders in the field of hematologic oncology. They will work with an editorial board comprising world-renowned experts to curate leading blood cancer research studies from labs and clinics all over the world for inclusion in this monthly journal.
Dr. Dalla-Favera is director of the Institute for Cancer Genetics at Columbia University and serves as professor of pathology and cell biology, microbiology and immunology, and genetics and development. He is an elected Fellow of the AACR Academy and recipient of the 2017 AACR G.H.A. Clowes Memorial Award. He is also a member of the National Academy of Medicine and the National Academy of Science. His work focuses on the pathogenesis of cancers derived from B lymphocytes, including the testing of novel therapeutic approaches for their ability to target newly discovered genetic lesions and cellular pathways altered in tumors. These discoveries have led to the development of diagnostic tests that are now being evaluated in clinical trials.
Dr. Anderson is program director at the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute and Kraft Family Professor of Medicine at Harvard Medical School. He is an elected Fellow of the AACR Academy and recipient of the 2007 AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research. He is also a member of the National Academy of Medicine. Over the last three decades, Anderson has focused his laboratory and clinical research studies on multiple myeloma, developing laboratory and animal models to better understand the biological mechanisms of the disease. These findings have been translated into clinical trials that culminated in U.S. Food and Drug Administration approval of novel targeted therapies.
The first print issue of Blood Cancer Discovery will be published early next year, and papers accepted for publication this year will be published online rapidly.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
